Ceftaroline-induced eosinophilic pneumonia

Pharmacotherapy

Volumn 33, Issue 7, 2013, Pages

  Desai, Kunal R ^a   Burdette, Steven D ^a   Polenakovik, Hari M ^a   Hagaman, Jared ^a   Pleiman, Craig M ^b  

^a WRIGHT STATE UNIVERSITY   (United States)

^b MIAMI VALLEY HOSPITAL   (United States)

Author keywords

Adverse event; Ceftaroline; Eosinophilic pneumonia

Indexed keywords

AZTREONAM; CEFTAROLINE; DOXYCYCLINE; METHYLPREDNISOLONE; PREDNISONE; TIGECYCLINE; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BONE INFECTION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FOLLOW UP; HUMAN; HYPOXEMIA; JOINT DEGENERATION; LOEFFLER PNEUMONIA; LOW BACK PAIN; LUMBAR SPINE; LUNG NODULE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE INFECTION; SPINAL CORD DECOMPRESSION; SPINE DISEASE; THORAX RADIOGRAPHY; TREATMENT DURATION;

ADVERSE EVENT; CEFTAROLINE; EOSINOPHILIC PNEUMONIA;

ANTI-BACTERIAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CEPHALOSPORINS; GLUCOCORTICOIDS; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PULMONARY EOSINOPHILIA; STAPHYLOCOCCAL INFECTIONS;

EID: 84885404644     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1286     Document Type: Article

References (13)

1. File TM Jr, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 2012;55(Suppl 3):S173-80.
2. Lin JC, Aung G, Thomas A, Jahng M, Johns S, Fierer J. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother 2013;19:42-9.
3. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS 2nd. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 2012;67:1267-70.
4. Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 2011;66(Suppl 3):iii53-9.
5. Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010;65(Suppl 4):iv67-71.
6. Solomon J, Schwarz M. Drug-, toxin-, and radiation therapyinduced eosinophilic pneumonia. Semin Respir Crit Care Med 2006;27:192-7.
7. Irie M, Teshima H, Matsuura T, et al. Pulmonary infiltration with eosinophilia possibly induced by cefotiam in a case of steroid- dependent asthma. Nihon Kyobu Shikkan Gakkai Zasshi 1990;28:1353-8.
8. Smith J, Weinstein V. Drug points: cephalexin associated pulmonary infiltration with circulating eosinophilia. Br Med J (Clin Res Ed) 1987;294(6574):776.
9. Dreis DF, Winterbauer RH, Van Norman GA, Sullivan SL, Hammar SP. Cephalosporin-induced interstitial pneumonitis. Chest 1984;86:138-40.
10. Allen JN. Drug-induced eosinophilic lung disease. Clin Chest Med 2004;25:77-88.
11. Ge Y, Hubbel A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (poster A-1935). Presented at: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, September 2006.
12. Jacqueline C, Caillon J, Miegeville AF, et al. Penetration of ceftaroline (PPI-0903), a new cephalosporin, into lung tissues: measurement of plasma and lung tissue concentrations after a short IV infusion in the rabbit. Abstract presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, September 27-30, 2006. Abstract A-1938.
13. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.